Merit Medical Systems (MMSI) 44th Annual J.P. Morgan Healthcare Conference summary

Leadership Transition and Strategic Direction

• New CEO Martha Aronson appointed in October 2025, succeeding the founder, with a new executive team and global operating committee established, emphasizing a transition from founder-led to founder-inspired leadership.

• Board leadership transitioned smoothly to F. Ann Millner as chair, with no anticipated strategic changes.

• CEO's early focus included a global listening tour, customer visits, global town halls, reinforcing infrastructure, and preparing for global scaling.

• Strategic planning for 2027–2030 underway, with a focus on global engagement and disciplined M&A.

• Strategy remains customer-focused, combining organic innovation and disciplined M&A.

Financial Performance and Growth Outlook

• Achieved $1.514 billion in 2025 revenue, with 11–12% GAAP growth and 11% constant currency growth.

• Revenue is globally diversified: 40% international, 60% U.S.

• Non-GAAP operating margin improved to 17.2% in 2025, targeting 20–22% by end of 2026.

• Cumulative free cash flow expected to exceed $400 million by end of 2026.

• 11% CAGR in total revenue from 2016 to 2025, driven by organic growth and tuck-in acquisitions.

Product Portfolio and Innovation

• 2025 revenue split: 68% foundational products (6% CAGR), 32% therapeutic products (19% CAGR) across cardiac, renal, vascular, oncology, and endoscopy.

• Cardiac therapies and vascular interventions are high-growth segments, supported by acquisitions like Cook Medical's lead extraction technology.

• Robust R&D engine supports innovation in high-growth therapeutic areas, including market-leading devices for dialysis, embolization, and breast cancer localization.

• WRAPSODY, a PMA-approved product for dialysis, is margin accretive, targets a U.S. market of ~95,000 stents annually, and demonstrated significant improvement in vessel patency in clinical trials.

• Product development is increasingly cross-functional, integrating R&D, marketing, and reimbursement expertise.